Novartis’ Blockbuster Zoledronic Acid – Overview of IP Situation and Litigation
GenericsWeb, the leader in established pharmaceutical patent analysis and searching, recently published an article based on its proprietary Pipeline Patent Intelligence that analyses opportunities in launching generic versions of Zoledronic Acid. Marketed by Novartis, Zoledronic Acid is indicated for the treatment of oncology-related bone conditions (Zometa®) and non-oncology related bone conditions (Reclast®/Aclasta®) with reported global sales of USD $1.5bn and USD $580m in 2010 respectively. Sydney, Australia (PRWEB) September 29, 2011 The article by GenericsWeb highlight
Contributor
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
Categories
- Articles 309
- Bankruptcy 44
- Business 134
- Cases & Codes 68
- Contracts 27
- Criminal Law 122
- Employment 24
- Expert Reports 3
- Expert Witness 34
- Family Law 57
- Form Letters 15
- Immigration 3
- Intellectual Prop 32
- Internet Law 10
- Law Practice 99
- Law School 2
- Legal Research 19
- Litigation 186
- Miscellaneous 64
- PR Web 41689
- Personal Injury 608
- Press Release 43
- Probate 54
- Real Estate 68
- Tax Law 23
- Workers Comp 4